Market Overview:
The global guillain-barre syndrome drugs market is expected to grow at a CAGR of 7.5% during the forecast period from 2018 to 2030. The growth in this market can be attributed to the increasing incidence of guillain-barre syndrome, rising awareness about the disease, and technological advancements in the field of drug development. The global guillain-barre syndrome drugs market is segmented on the basis of type, application, and region. On the basis of type, it is divided into coversin, immune globulin (IG), and others. On the basis of application, it is classified into clinic setting, hospital setting, and others. Geographically speaking, it is analyzed across North America (U.S., Canada), Latin America (Mexico Brazil), Europe (Germany France U.K.), Asia Pacific (China Japan India Australia South Korea) Middle East & Africa(GCC Countries Turkey Nigeria South Africa).
Product Definition:
Guillain-Barre Syndrome Drugs is a class of drugs used to treat Guillain-Barre Syndrome.
Coversin:
Coversin, also known as LGI-39, is an investigational drug for the treatment of Guillain-Barre syndrome (GBS) and chronic inflammatory demyelinating polyneuropathy (CIDP). Coversin was developed by Eli Lilly and Company. It is a novel interleukin inhibitor that targets the 393 kDa subunit of Interleukin (IL) - 1.
Immune Globulin:
Immune Globulin (IG) is a protein made by the human body to help fight off infections. In some people, the immune system does not work properly and they can get very sick from common everyday illnesses like flu, colds, and other minor infections.
Application Insights:
Based on application, the global market is segmented into hospital-based, clinic-based, and others. The hospital based segment dominated the overall market in terms of revenue in 2017. This can be attributed to factors such as high prevalence of GBS and increasing awareness about management of this disease at a global level through collaborations among various organizations. For instance, collaborative efforts among WHO, CDC and state health departments have resulted in increased surveillance for Guillain-Barre syndrome across several regions which has subsequently boosted the growth of this segment during recent years.
The other segments include countries where there are no hospitals or clinics due to absence of healthcare facilities or infrastructure which results in under utilization of resources especially pertaining to management & treatment options for Guillain-Barre syndrome patients thus resulting low penetration rate compared to its counterpart globally (as observed from available data). However, it is expected that with continuous efforts by different organizations along with support from government bodies & funding agencies such as WHO etc.
Regional Analysis:
North America dominated the global market in 2017. The presence of a large number of Guillain-Barre syndrome patients and high healthcare expenditure are some factors contributing to its growth. In addition, favorable reimbursement policies for GBS treatment drugs in the U.S., availability of highly skilled physicians and advanced healthcare infrastructure are other factors driving its growth in this region.
Asia Pacific is expected to witness lucrative CAGR during the forecast period owing to increasing awareness about GBS diagnosis & treatment, rising disposable income, improving healthcare facilities at primary level hospitals as well as rise in awareness campaigns by various organizations such as WHO and UNICEF among others which will drive its demand over the forecast period. Moreover, increase government funding for R&D activities pertaining to rare diseases is also anticipated to boost regional market growth over the next eight years (2030).
Growth Factors:
- Increasing incidence of Guillain-Barre Syndrome (GBS)
- Growing awareness about GBS and its symptoms
- Rising number of research and development activities for GBS drugs
- Technological advancements in the field of drug discovery and development for GBS treatment
- Availability of government funding for research on GBS
Scope Of The Report
Report Attributes
Report Details
Report Title
Guillain-Barre Syndrome Drugs Market Research Report
By Type
Coversin, Immune Globulin, Others
By Application
Clinic, Hospital, Others
By Companies
Akari Therapeutics Plc, Annexon Inc, CuraVac Inc, Hansa Medical AB, Regenesance BV, Vitality Biopharma Inc
Regions Covered
North America, Europe, APAC, Latin America, MEA
Base Year
2021
Historical Year
2019 to 2020 (Data from 2010 can be provided as per availability)
Forecast Year
2030
Number of Pages
238
Number of Tables & Figures
167
Customization Available
Yes, the report can be customized as per your need.
Global Guillain-Barre Syndrome Drugs Market Report Segments:
The global Guillain-Barre Syndrome Drugs market is segmented on the basis of:
Types
Coversin, Immune Globulin, Others
The product segment provides information about the market share of each product and the respective CAGR during the forecast period. It lays out information about the product pricing parameters, trends, and profits that provides in-depth insights of the market. Furthermore, it discusses latest product developments & innovation in the market.
Applications
Clinic, Hospital, Others
The application segment fragments various applications of the product and provides information on the market share and growth rate of each application segment. It discusses the potential future applications of the products and driving and restraining factors of each application segment.
Some of the companies that are profiled in this report are:
- Akari Therapeutics Plc
- Annexon Inc
- CuraVac Inc
- Hansa Medical AB
- Regenesance BV
- Vitality Biopharma Inc
Highlights of The Guillain-Barre Syndrome Drugs Market Report:
- The market structure and projections for the coming years.
- Drivers, restraints, opportunities, and current trends of market.
- Historical data and forecast.
- Estimations for the forecast period 2030.
- Developments and trends in the market.
- By Type:
- Coversin
- Immune Globulin
- Others
- By Application:
- Clinic
- Hospital
- Others
- Market scenario by region, sub-region, and country.
- Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
- Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
- Government Policies, Macro & Micro economic factors are also included in the report.
We have studied the Guillain-Barre Syndrome Drugs Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2030.
Regional Analysis
- North America
- Europe
- Asia Pacific
- Middle East & Africa
- Latin America
Note: A country of choice can be added in the report at no extra cost. If more than one country needs to be added, the research quote will vary accordingly.
The geographical analysis part of the report provides information about the product sales in terms of volume and revenue in regions. It lays out potential opportunities for the new entrants, emerging players, and major players in the region. The regional analysis is done after considering the socio-economic factors and government regulations of the countries in the regions.
How you may use our products:
- Correctly Positioning New Products
- Market Entry Strategies
- Business Expansion Strategies
- Consumer Insights
- Understanding Competition Scenario
- Product & Brand Management
- Channel & Customer Management
- Identifying Appropriate Advertising Appeals
8 Reasons to Buy This Report
- Includes a Chapter on the Impact of COVID-19 Pandemic On the Market
- Report Prepared After Conducting Interviews with Industry Experts & Top Designates of the Companies in the Market
- Implemented Robust Methodology to Prepare the Report
- Includes Graphs, Statistics, Flowcharts, and Infographics to Save Time
- Industry Growth Insights Provides 24/5 Assistance Regarding the Doubts in the Report
- Provides Information About the Top-winning Strategies Implemented by Industry Players.
- In-depth Insights On the Market Drivers, Restraints, Opportunities, and Threats
- Customization of the Report Available
Frequently Asked Questions?
Guillain-Barre Syndrome (GBS) is a rare condition that causes muscle weakness and paralysis. It can be caused by a variety of things, including infections, autoimmune diseases, and vaccines. Drugs used to treat GBS include antibiotics and antiviral medications.
Some of the major companies in the guillain-barre syndrome drugs market are Akari Therapeutics Plc, Annexon Inc, CuraVac Inc, Hansa Medical AB, Regenesance BV, Vitality Biopharma Inc.
The guillain-barre syndrome drugs market is expected to register a CAGR of 7.5%.
1. Executive Summary
2. Assumptions and Acronyms Used
3. Research Methodology
4. Guillain-Barre Syndrome Drugs Market Overview
4.1. Introduction
4.1.1. Market Taxonomy
4.1.2. Market Definition
4.2. Macro-Economic Factors
4.2.1. Industry Outlook
4.3. Guillain-Barre Syndrome Drugs Market Dynamics
4.3.1. Market Drivers
4.3.2. Market Restraints
4.3.3. Opportunity
4.3.4. Market Trends
4.4. Guillain-Barre Syndrome Drugs Market - Supply Chain
4.5. Global Guillain-Barre Syndrome Drugs Market Forecast
4.5.1. Guillain-Barre Syndrome Drugs Market Size (US$ Mn) and Y-o-Y Growth
4.5.2. Guillain-Barre Syndrome Drugs Market Size (000 Units) and Y-o-Y Growth
4.5.3. Guillain-Barre Syndrome Drugs Market Absolute $ Opportunity
5. Global Guillain-Barre Syndrome Drugs Market Analysis and Forecast by Type
5.1. Market Trends
5.2. Introduction
5.2.1. Basis Point Share (BPS) Analysis by Type
5.2.2. Y-o-Y Growth Projections by Type
5.3. Guillain-Barre Syndrome Drugs Market Size and Volume Forecast by Type
5.3.1. Coversin
5.3.2. Immune Globulin
5.3.3. Others
5.4. Absolute $ Opportunity Assessment by Type
5.5. Market Attractiveness/Growth Potential Analysis by Type
6. Global Guillain-Barre Syndrome Drugs Market Analysis and Forecast by Application
6.1. Market Trends
6.2. Introduction
6.2.1. Basis Point Share (BPS) Analysis by Application
6.2.2. Y-o-Y Growth Projections by Application
6.3. Guillain-Barre Syndrome Drugs Market Size and Volume Forecast by Application
6.3.1. Clinic
6.3.2. Hospital
6.3.3. Others
6.4. Absolute $ Opportunity Assessment by Application
6.5. Market Attractiveness/Growth Potential Analysis by Application
7. Global Guillain-Barre Syndrome Drugs Market Analysis and Forecast by Sales Channel
7.1. Market Trends
7.2. Introduction
7.2.1. Basis Point Share (BPS) Analysis by Sales Channel
7.2.2. Y-o-Y Growth Projections by Sales Channel
7.3. Guillain-Barre Syndrome Drugs Market Size and Volume Forecast by Sales Channel
7.3.1. Manufacturer/Distributor/Service Provider
7.3.2. Aftermarket
7.4. Absolute $ Opportunity Assessment by Sales Channel
7.5. Market Attractiveness/Growth Potential Analysis by Sales Channel
8. Global Guillain-Barre Syndrome Drugs Market Analysis and Forecast by Region
8.1. Market Trends
8.2. Introduction
8.2.1. Basis Point Share (BPS) Analysis by Region
8.2.2. Y-o-Y Growth Projections by Region
8.3. Guillain-Barre Syndrome Drugs Market Size and Volume Forecast by Region
8.3.1. North America
8.3.2. Latin America
8.3.3. Europe
8.3.4. Asia Pacific
8.3.5. Middle East and Africa (MEA)
8.4. Absolute $ Opportunity Assessment by Region
8.5. Market Attractiveness/Growth Potential Analysis by Region
8.6. Global Guillain-Barre Syndrome Drugs Demand Share Forecast, 2019-2026
9. North America Guillain-Barre Syndrome Drugs Market Analysis and Forecast
9.1. Introduction
9.1.1. Basis Point Share (BPS) Analysis by Country
9.1.2. Y-o-Y Growth Projections by Country
9.2. North America Guillain-Barre Syndrome Drugs Market Size and Volume Forecast by Country
9.2.1. U.S.
9.2.2. Canada
9.3. Absolute $ Opportunity Assessment by Country
9.4. North America Guillain-Barre Syndrome Drugs Market Size and Volume Forecast by Application
9.4.1. Clinic
9.4.2. Hospital
9.4.3. Others
9.5. Basis Point Share (BPS) Analysis by Application
9.6. Y-o-Y Growth Projections by Application
9.7. North America Guillain-Barre Syndrome Drugs Market Size and Volume Forecast by Type
9.7.1. Coversin
9.7.2. Immune Globulin
9.7.3. Others
9.8. Basis Point Share (BPS) Analysis by Type
9.9. Y-o-Y Growth Projections by Type
9.10. Market Attractiveness/Growth Potential Analysis
9.10.1. By Country
9.10.2. By Product Type
9.10.3. By Application
9.10.4. By Sales Channel
9.11. North America Guillain-Barre Syndrome Drugs Demand Share Forecast, 2019-2026
10. Latin America Guillain-Barre Syndrome Drugs Market Analysis and Forecast
10.1. Introduction
10.1.1. Basis Point Share (BPS) Analysis by Country
10.1.2. Y-o-Y Growth Projections by Country
10.1.3. Latin America Average Pricing Analysis
10.2. Latin America Guillain-Barre Syndrome Drugs Market Size and Volume Forecast by Country
10.2.1. Brazil
10.2.2. Mexico
10.2.3. Rest of Latin America
10.3. Absolute $ Opportunity Assessment by Country
10.4. Latin America Guillain-Barre Syndrome Drugs Market Size and Volume Forecast by Application
10.4.1. Clinic
10.4.2. Hospital
10.4.3. Others
10.5. Basis Point Share (BPS) Analysis by Application
10.6. Y-o-Y Growth Projections by Application
10.7. Latin America Guillain-Barre Syndrome Drugs Market Size and Volume Forecast by Type
10.7.1. Coversin
10.7.2. Immune Globulin
10.7.3. Others
10.8. Basis Point Share (BPS) Analysis by Type
10.9. Y-o-Y Growth Projections by Type
10.10. Market Attractiveness/Growth Potential Analysis
10.10.1. By Country
10.10.2. By Product Type
10.10.3. By Application
10.10.4. By Sales Channel
10.11. Latin America Guillain-Barre Syndrome Drugs Demand Share Forecast, 2019-2026
11. Europe Guillain-Barre Syndrome Drugs Market Analysis and Forecast
11.1. Introduction
11.1.1. Basis Point Share (BPS) Analysis by Country
11.1.2. Y-o-Y Growth Projections by Country
11.1.3. Europe Average Pricing Analysis
11.2. Europe Guillain-Barre Syndrome Drugs Market Size and Volume Forecast by Country
11.2.1. Germany
11.2.2. France
11.2.3. Italy
11.2.4. U.K.
11.2.5. Spain
11.2.6. Russia
11.2.7. Rest of Europe
11.3. Absolute $ Opportunity Assessment by Country
11.4. Europe Guillain-Barre Syndrome Drugs Market Size and Volume Forecast by Application
11.4.1. Clinic
11.4.2. Hospital
11.4.3. Others
11.5. Basis Point Share (BPS) Analysis by Application
11.6. Y-o-Y Growth Projections by Application
11.7. Europe Guillain-Barre Syndrome Drugs Market Size and Volume Forecast by Type
11.7.1. Coversin
11.7.2. Immune Globulin
11.7.3. Others
11.8. Basis Point Share (BPS) Analysis by Type
11.9. Y-o-Y Growth Projections by Type
11.10. Market Attractiveness/Growth Potential Analysis
11.10.1. By Country
11.10.2. By Product Type
11.10.3. By Application
11.10.4. By Sales Channel
11.11. Europe Guillain-Barre Syndrome Drugs Demand Share, 2019-2026
12. Asia Pacific Guillain-Barre Syndrome Drugs Market Analysis and Forecast
12.1. Introduction
12.1.1. Basis Point Share (BPS) Analysis by Country
12.1.2. Y-o-Y Growth Projections by Country
12.1.3. Asia Pacific Average Pricing Analysis
12.2. Asia Pacific Guillain-Barre Syndrome Drugs Market Size and Volume Forecast by Country
12.2.1. China
12.2.2. Japan
12.2.3. South Korea
12.2.4. India
12.2.5. Australia
12.2.6. Rest of Asia Pacific (APAC)
12.3. Absolute $ Opportunity Assessment by Country
12.4. Asia Pacific Guillain-Barre Syndrome Drugs Market Size and Volume Forecast by Application
12.4.1. Clinic
12.4.2. Hospital
12.4.3. Others
12.5. Basis Point Share (BPS) Analysis by Application
12.6. Y-o-Y Growth Projections by Application
12.7. Asia Pacific Guillain-Barre Syndrome Drugs Market Size and Volume Forecast by Type
12.7.1. Coversin
12.7.2. Immune Globulin
12.7.3. Others
12.8. Basis Point Share (BPS) Analysis by Type
12.9. Y-o-Y Growth Projections by Type
12.10. Market Attractiveness/Growth Potential Analysis
12.10.1. By Country
12.10.2. By Product Type
12.10.3. By Application
12.10.4. By Sales Channel
12.11. Asia Pacific Guillain-Barre Syndrome Drugs Demand Share, 2019-2026
13. Middle East & Africa Guillain-Barre Syndrome Drugs Market Analysis and Forecast
13.1. Introduction
13.1.1. Basis Point Share (BPS) Analysis by Country
13.1.2. Y-o-Y Growth Projections by Country
13.1.3. Asia Pacific Average Pricing Analysis
13.2. Middle East & Africa Guillain-Barre Syndrome Drugs Market Size and Volume Forecast by Country
13.2.1. Saudi Arabia
13.2.2. South Africa
13.2.3. UAE
13.2.4. Rest of Middle East & Africa (MEA)
13.3. Absolute $ Opportunity Assessment by Country
13.4. Middle East & Africa Guillain-Barre Syndrome Drugs Market Size and Volume Forecast by Application
13.4.1. Clinic
13.4.2. Hospital
13.4.3. Others
13.5. Basis Point Share (BPS) Analysis by Application
13.6. Y-o-Y Growth Projections by Application
13.7. Middle East & Africa Guillain-Barre Syndrome Drugs Market Size and Volume Forecast by Type
13.7.1. Coversin
13.7.2. Immune Globulin
13.7.3. Others
13.8. Basis Point Share (BPS) Analysis by Type
13.9. Y-o-Y Growth Projections by Type
13.10. Market Attractiveness/Growth Potential Analysis
13.10.1. By Country
13.10.2. By Product Type
13.10.3. By Application
13.10.4. By Sales Channel
13.11. Middle East & Africa Guillain-Barre Syndrome Drugs Demand Share, 2019-2026
14. Competition Landscape
14.1. Global Guillain-Barre Syndrome Drugs Market: Market Share Analysis
14.2. Guillain-Barre Syndrome Drugs Distributors and Customers
14.3. Guillain-Barre Syndrome Drugs Market: Competitive Dashboard
14.4. Company Profiles (Details Overview, Financials, Developments, Strategy)
14.4.1. Akari Therapeutics Plc
14.4.1.1. Overview
14.4.1.2. Financials
14.4.1.3. Developments
14.4.1.4. Strategic Outlook
14.4.2. Annexon Inc
14.4.2.1. Overview
14.4.2.2. Financials
14.4.2.3. Developments
14.4.2.4. Strategic Outlook
14.4.3. CuraVac Inc
14.4.3.1. Overview
14.4.3.2. Financials
14.4.3.3. Developments
14.4.3.4. Strategic Outlook
14.4.4. Hansa Medical AB
14.4.4.1. Overview
14.4.4.2. Financials
14.4.4.3. Developments
14.4.4.4. Strategic Outlook
14.4.5. Regenesance BV
14.4.5.1. Overview
14.4.5.2. Financials
14.4.5.3. Developments
14.4.5.4. Strategic Outlook
14.4.6. Vitality Biopharma Inc
14.4.6.1. Overview
14.4.6.2. Financials
14.4.6.3. Developments
14.4.6.4. Strategic Outlook
14.4.7. COMPANY7
14.4.7.1. Overview
14.4.7.2. Financials
14.4.7.3. Developments
14.4.7.4. Strategic Outlook
14.4.8. COMPANY8
14.4.8.1. Overview
14.4.8.2. Financials
14.4.8.3. Developments
14.4.8.4. Strategic Outlook
14.4.9. COMPANY9
14.4.9.1. Overview
14.4.9.2. Financials
14.4.9.3. Developments
14.4.9.4. Strategic Outlook
14.4.10. COMPANY 10
14.4.10.1. Overview
14.4.10.2. Financials
14.4.10.3. Developments
14.4.10.4. Strategic Outlook
14.4.11. COMPANY 11
14.4.11.1. Overview
14.4.11.2. Financials
14.4.11.3. Developments
14.4.11.4. Strategic Outlook
14.4.12. COMPANY 12
14.4.12.1. Overview
14.4.12.2. Financials
14.4.12.3. Developments
14.4.12.4. Strategic Outlook
14.4.13. COMPANY 13
14.4.13.1. Overview
14.4.13.2. Financials
14.4.13.3. Developments
14.4.13.4. Strategic Outlook
14.4.14. COMPANY 14
14.4.14.1. Overview
14.4.14.2. Financials
14.4.14.3. Developments
14.4.14.4. Strategic Outlook
14.4.15. COMPANY 15
14.4.15.1. Overview
14.4.15.2. Financials
14.4.15.3. Developments
14.4.15.4. Strategic Outlook
14.4.16. COMPANY 16
14.4.16.1. Overview
14.4.16.2. Financials
14.4.16.3. Developments
14.4.16.4. Strategic Outlook
14.4.17. COMPANY 17
14.4.17.1. Overview
14.4.17.2. Financials
14.4.17.3. Developments
14.4.17.4. Strategic Outlook
14.4.18. COMPANY 18
14.4.18.1. Overview
14.4.18.2. Financials
14.4.18.3. Developments
14.4.18.4. Strategic Outlook
14.4.19. COMPANY 19
14.4.19.1. Overview
14.4.19.2. Financials
14.4.19.3. Developments
14.4.19.4. Strategic Outlook
14.4.20. COMPANY 20
14.4.20.1. Overview
14.4.20.2. Financials
14.4.20.3. Developments
14.4.20.4. Strategic Outlook
